Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thyroid
Autors principals: Ito, Yasuhiro, Onoda, Naoyoshi, Ito, Ken-ichi, Sugitani, Iwao, Takahashi, Shunji, Yamaguchi, Iku, Kabu, Koki, Tsukada, Katsuya
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2017
Matèries:
Thyroid Cancer and Nodules
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5646744/
https://ncbi.nlm.nih.gov/pubmed/28635560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2016.0621
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars